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Abstract
Objective: Despite having an organ confined tumor
stage at the time of radical cystectomy, a certain num-
ber of bladder cancer patients will develop local or
distant metastases over time. Currently there are no re-
liable serum markers for monitoring and evaluating
risk profiles of urothelial cancers. Several studies sug-
gest that detection of Circulating Tumor Cells (CTC)
may correlate with disease status and prognosis at
baseline and early in the treatment of cancers. The
presence of CTCs in whole blood before and during
radical cystectomy could provide further information
on disease status, and could be used as an indicator to
determine the need for adjuvant or even perioperative
chemotherapy.
Methods: From 03/2009 to 05/2009, five patients with
histologically proven transitional cell carcinoma of the
urinary bladder participated in this study. All patients
were admitted to the hospital for radical cystectomy
(rCx). A standard or extended lymph node dissection
was performed in all cases. Preoperative CT or MRI
scans revealed no distant or local metastases. Median
age was 66.8 years (55-81 yrs). After obtaining in-
formed consent from each patient, approximately 30
mL of peripheral blood was taken immediately before
rCx and again during surgical removal of the urinary
bladder from the patients´ body. As additional para-
meters, operation time (OR) for surgical removal of
the bladder and the amount of blood volume that was
used for the detection of CTCs were recorded. Ob-
tained blood samples were processed using the Cell-
Search System (Veridex©) within 48 hours of collec-
tion. CTCs were identified and quantitated using the
Cell-Search System, followed by re-evaluation of the
provided results by specially trained and experienced
personal. (CS, SH)
Results: CTCs were detected before and during surgi-
cal removal of the urinary bladder in one of five pa-
tients (20%). In the one patient positive for CTC, two
CTCs were detected in the blood sample that was ob-
tained before surgery (analyzed blood volume was 25
mL). There was one CTC detected in the blood sam-
ple that was obtained during surgical removal of the
urinary bladder (analyzed blood volume was 27
mL).There was no rise in the amount of CTCs during
surgical procedure. The final pathological report of
this patient showed an advanced tumor stage (T3b,
N0, R1). In the other patients, no CTCs were detected
at all, neither before rCX nor right after surgical re-
moval of the bladder. Pathological stage for these pa-
tients ranged from pT1m G3 - pT2b G3. None of
these patients showed lymph node involvement. An
average of 14.6 lymph nodes (5-40 LNs) were ob-
tained. OR time to surgical removal of the urinary
bladder ranged from 60 minutes to 150 minutes (mean
82 min.).
Conclusions: Although only a very small group of pa-
tients was analyzed in this study, the presence of
CTCs seems to be correlated with an advanced tumor
stage. Therefore the detection of CTCs could be used
for an optimized assessment of a patient’s disease sta-
tus in urothelial cancer. A further aim of this study
was to assess whether surgical manipulation during
radical cystectomy is associated with a release of CTCs
into the vascular system. None of the patients who
were negative for CTCs before surgery showed CTCs
during surgical removal of the bladder, suggesting that
there was no release of CTCs during surgery. Howev-
er, further study is needed to prove these findings and
evaluate the significance of CTCs as an indicator for
therapeutic decisions.
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INTRODUCTION
Carcinoma of the urinary bladder is the fifth most fre-
quent malignant disease in the Western World. In the
US approximately 70,980 new cases of bladder cancer
will be diagnosed and 14,330 people will die from this
disease in 2009 [1]. Around 75% of patients are diag-
nosed initially with non-muscle-invasive tumors that
can be treated locally with transurethral tumor resec-
tion, but 50-70% of these patients show recurrence
within the first 2 years after initial diagnosis [2].
Generally, in most countries radical cystectomy
(rCx) represents the gold standard treatment for mus-
cle-invasive bladder cancer. However approximately
one third of patients diagnosed with muscle-invasive
bladder cancer have undetected metastases at the time
of treatment of the primary tumor [3], and 25% of
patients treated by radical cystectomy present with
lymph node involvement at the time of surgery [4].
In addition, approximately 50% of patients with
muscle-invasive urothelial cancer develop metastases
within 2 years of operation and subsequently die of
the disease [5].
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over time despite an organ confined primary tumor
stage, there is a definite need for new diagnostic tools
that more accurately reflect the patient’s actual disease
status. Identifying those patients who are more sus-
ceptible to development of metastases over time
could lead to optimization of therapeutic manage-
ment.
In this study we hypothesized that the presence of
CTCs before or even during radical rCx (due to surgi-
cal manipulation) could give further insight into the
patient’s actual disease status. The presence of CTCs
could potentially be an indicator of eventual tumor
behavior. Based on the detection of CTCs during rCx
a more aggressive individualized therapy regimen
could be initiated which could lead to an improvement
in clinical outcome. As surgical manipulation and man-
ual compression of the tumorous area could be associ-
ated with the release of tumor cells into the vascular
system, this study aimed to measure whether CTCs
could be detected during the surgical removal of the
urinary bladder.
To our knowledge this is the first study that aims to
detect CTCs in patients with urothelial cell carcinoma
during the performance of radical cystectomy.
MATERIAL AND METHODS
In this pilot study we included five patients with previ-
ously histologically proven transitional cell carcinoma
of the urinary bladder. All patients warranted radical
cystectomy due to their tumor stages. Preoperative tu-
mor stages ranged from a multifocal T1 G3 tumor to
T2 G3 tumors. All patients underwent radical cystec-
tomy at our institution sometime between 03/2009
and 05/2009. Two men and three women were includ-
ed, median age was 66.8 years (55-81 yrs). After in-
formed consent, approximately 30 mL of peripheral
blood was obtained using three Cell Safe Preservation
Tubes (Immunicon, Huntingdon Valley, PA©) before
the performance of radical cystectomy and again dur-
ing the surgical removal of the urinary bladder from
the patient’s body. The time from the beginning of the
operation to the actual surgical removal of the urinary
bladder was recorded for each patient as an indirect in-
dicator for the intensity of surgical manipulation. The
exact blood volume used for detection of CTCs was
recorded for each patient. A standard or extended
lymph node dissection was performed. All patients
were preoperatively staged (CT/MRI scan) by an ex-
perienced radiologist as negative for local or distant
metastases.
ISOLATION AND ENUMERATION OF CTCS
Blood samples were maintained at room temperature
and processed using the CellSearch System within 48
hours of collection [6]. The Cell Search System (Im-
municon©, Huntingdon Valley, PA) was used for iso-
lation and enumeration of CTCs. This system works
semi-automatically to prepare the sample. The pro-
cedure enriches the sample for cells expressing
EpCAM using antibody-coated magnetic beads and
labels these cells with a fluorescent nucleic acid dye
4´,6-diamidino-2-phenylindole (DAPI). Fluorescent-
labeled monoclonal antibodies specific for leukocytes
(CD45-allophycocyan) and epithelial cells (cytokeratin
8,18,19-phycoerythrin) are used to distinguish epithe-
lial cells from leukocytes. The identification and quan-
tification of circulating tumor cells was performed by
a semi-automated fluorescence based microscopy sys-
tem that enables computer generated reconstruction
of cellular images. Afterwards, the hits that were gen-
erated by the system were reevaluated by specially
trained and experienced personal (CS,SH).
CTC DEFINITION
To qualify as a CTC, an object must be round or oval,
have a nucleus (as determined by positive 4´,6-diamidi-
no-2-phenylindole staining) contained within the cyto-
plasm (as determined by positive cytokeratin 8,18,19
–phycoerythrin staining), and lack expression of
CD45 (as determined by negative CD45-allophyco-
cyanin staining).
RESULTS
Using the Cell-Search System (Veridex©), CTCs were
detected before and during surgical removal of the
urinary bladder in one of five patients (20%). In the
one patient positive for CTCs, two CTCs were detect-
ed in the sample obtained before rCx (analyzed sample
volume of 25 mL). In the blood sample obtained dur-
ing surgical removal of the urinary bladder only one
CTC was detected in a sample volume of 27 mL. The
final pathological report for this patient showed an ad-
vanced tumor stage (T3b, N0, R1). However, no rise in
the number of CTCs was observed during rCx.
No CTCs were detected in the 4 other patients in-
cluded in the study, neither before rCX nor right after
surgical removal of the bladder. Pathological stage for
these patients ranged from pT1m G3 - pT2b G3.
None of these patients showed lymph node involve-
ment (patient details see Table 1). On average, 14.6
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Table 1. Patient details and final pathological results.
Pt Nr Gender Age Tumor Grading LN CTC pre CTC during OR time (min) to surg.
stage status OP OP removal of the bladder
1m58 pT3b G3-4 02 1 150
2w69 pT1G3m G3 00 0 70
3w82 pT2b G3 00 0 60
4w70 pT2a G3 00 0 60
5m55 pT2a, Cis G3 00 0 70
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surgical removal of the urinary bladder was measured
as an indirect correlate for surgical manipulation. OR
time to bladder removal ranged from 60 minutes to
150 minutes (mean 82 minutes).
DISCUSSION
In most countries, radical cystectomy generally repre-
sents the gold standard treatment for muscle-invasive
bladder cancer. Based on older trial results, a Cochrane
systematic review [7] suggested an overall survival
benefit with radical surgery versus radiotherapy in pa-
tients with muscle-invasive bladder cancer. However,
despite advances in therapy and the institution of mul-
ti-modality therapy, survival rates for bladder cancer,
particularly for muscle invasive and advanced disease,
have not improved over the last two decades.
Five-year survival rates of 36-54% have been re-
ported in cystectomy series from major academic cen-
ters [8-11]. Chemotherapy has been used both as an
adjuvant to surgery and radiation, in a neoadjuvant
manner before surgery or along with radiation therapy.
Several trials show benefits for adjuvant chemothera-
py. However, the results are controversial because of
the small sample sizes and confusing analyses and trial
designs [12].
Circulating tumor cells have been documented in
the circulation of cancer patients since 1869 and dis-
cussed in more than 1500 publications. Attempts have
been made to detect cancer cells in the blood, bone
marrow, or lymph nodes using present PCR tech-
niques for various malignant tumors. However, identi-
fication of cancer cell DNA by PCR is laborious, re-
quires very specialized techniques and is not consis-
tently reproducible. Using PCR may be ultrasensitive
and not always specific, leading to identification of ab-
normal DNA that may not necessarily be associated
with the cancer cell in question. Identification of
CTCs is an alternative to PCR, allowing direct detec-
tion of CTCs using immunological technology. This
technique seems to be easier, more reliable, and rea-
sonable in terms of cost because it can be automated.
Studies on the detection of CTCs have been per-
formed for different malignancies such as breast,
colon, prostate and several others [13-15]. CTCs may
even represent an earlier and more reproducible indi-
cation of disease status than current imaging modali-
ties as shown by Budd et al. in a study on metastatic
breast cancer [16]. In prostate cancer, higher number
of CTCs was shown to be associated with poorer out-
comes [17]. The presence and number of CTCs seems
to correlate with chemotherapy response much earlier
than standard radiographic studies; benefit in terms of
long-term survival for prostate cancer patients is seen
when the CTC count decreases in response to chemo-
therapy just 2–5 weeks after starting chemotherapy
[18].
The CTC detection system was used in this study
represents a semi automated technique using immuno-
magnetic capture to detect CTCs. The basis for the de-
tection of urothelial cancer cells in peripheral blood is
that carcinoma cells differ from leukocytes in their
gene expression, and each of these cell populations
has tissue-specific antigens on the cell surface. The
Cell-Search System (Immunicon, Huntingdon Valley,
PA©) combines immunomagnetic enrichment with
multiparameter flow cytometric and immunocyto-
chemical analysis. Use of the Cell-Search System for
prediction of survival in metastatic breast cancer was
approved by the US Food and Drug Administration
(FDA) in 2004. The system uses magnetically-labeled
anti-EpCAM microbeads and immunocytochemical
staining for cytokeratin and CD45. Among epithelial
neoplasms, urothelial carcinoma is known to express
relatively high levels of EpCAM. An advantage of this
detection technique is that it is reproducible across
different laboratories and can identify CTCs in differ-
ent cancer types [19].
Naoe et al. [20] first demonstrated that urothelial
cancer cells can be distinguished from leukocytes by
using EpCAM and CD45 antibodies through flow cy-
tometric analysis. They found that it is possible to
identify bladder cancer cells among peripheral blood
mononuclear cells. They demonstrated that the sensi-
tivity for detection of urothelial cancer cells with Cell-
Search System using single regression analysis of the
spiked number of cells vs. the recovered number of
cells yielded a good correlation. Urothelial cancer cells
were detected in 8 of fourteen patients (57.1%) with
distant metastasis. These data show that Cell-Search
System enables the reliable detection of CTC in blood
and seems suitable for assessment of urothelial cancer
patients. Also, Gallagher et al. [21] recently reported
on the successful detection of CTCs in patients with
TCC using the Cell-Search System. They showed that
CTCs were detected by antibody capture technology in
44% of patients with metastatic TCC. Higher numbers
of CTCs were seen in patients with a greater number
of metastatic sites. One-third of patients had five or
more CTCs, providing a potential early marker to
monitor response to chemotherapy.
To our knowledge this is the first study aiming to
detect CTCs during performance of radical cystecto-
my. All patients were staged initially to be negative for
local or distant metastases using CT/MRI scanning.
One patient revealed an advanced tumor stage (T3b,
N0, R1) in the final pathological report. This patient
turned out to be the one in whom CTCs were detected
using the Cell-Search System before and during rCx,
suggesting that CTCs could be used as a sensitive tool
for the assessment of actual disease status.
Current literature reports demonstrating that CTCs
were found only in patients with advanced and
metastatic disease were confirmed in our study, as all
patients negative for CTCs before radical cystectomy
had histologically proven organ confined tumor stages.
Our hypothesis that surgical manipulation during
rCx could be associated with a release of CTCs into
the vascular system was not supported by the obtained
results. No CTCs were detected at the time of surgical
removal of the bladder from the patient’s body in pa-
tients with localized disease. Also in the one patient
positive for CTCs before the operation, no rise in
CTCs at the time of surgical removal of the urinary
bladder was detected. Therefore we assume that surgi-
cal manipulation did not lead to an additional release
of tumor cells into the vascular system. It seems un-
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release of tumor cells into the vascular system that
could be responsible for later development of metas-
tases. To indirectly evaluate the intensity of surgical
manipulation of the tumor area during the operation,
we recorded the time taken to complete removal of
the urinary bladder from the patient’s body. The time
to surgical removal ranged from 60 to 150 minutes
and was not associated with the presence of circulat-
ing tumor cells.
As this is a very small study cohort we can not ex-
clude the possibility of tumor cell release into the vas-
cular system during rCx, however from this dataset it
seems to be unlikely. Further prospective studies with
higher patient numbers would be needed to confirm
our conclusions. Nevertheless CTCs could be used as
a tool for improved assessment of a patient’s disease
status and could become the basis for optimization
and individualization of therapeutic decision making
in the future.
CONCLUSIONS
Although only a very small group of patients was ana-
lyzed in this study, the presence of CTCs seems to be
correlated with advanced tumor stage in patients with
TCC. Therefore CTCs could be used as a tool for im-
proved assessment of a patient’s disease status. A fur-
ther aim of this study was to assess whether surgical
manipulation during radical cystectomy is associated
with a release of CTCs into the vascular system. None
of the patients who were negative for CTCs before
surgery showed CTCs right after surgical removal of
the bladder, suggesting that there was no release of
CTCs during surgery. However further study is needed
to prove these findings and evaluate the significance of
CTCs as an indicator for therapeutic decision making.
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